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Abstract. The objective of the present study was to determine whether the development of behavioral sensitization to apomorphine could be blocked by either D 1 or
D 2 selective dopamine antagonists. In three experiments,
male rats received IG--21 daily injections of a selective D 1
(SCH 23390; 0 or 0.5 mg/kg IP) or D 2 (sulpiride; 0, 30,
or 100 mg/kg IP) antagonist followed by an apomorphine (0 or l.O mg/kg SC) injection. In two experiments,
the rats were tested for locomotor activity in photocell
arenas after the daily injections. In all experiments, the
rats were tested for sensitization to apomorphine following the training phase. The results indicated that apomorphine produced a progressively greater increase in
locomotor activity with each injection, and this apomorphine-induced increase in activity was completely
blocked by both sulpiride and SCH 23390 treatments.
However, although both sulpiride and SCH 23390
blocked apomorphine-induced activity, only SCH 23390
injections prevented the development of sensitization to
apomorphine. That is, rats pretreated with sulpiride
and apomorphine displayed significant sensitization
when subsequently tested with a challenge dose of apomorphine alone. These findings suggest that the development of behavioral sensitization to apomorphine is related specifically to the stimulation of dopamine D 1 receptors.
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The acute administration of direct (e.g., apomorphine)
and indirect (e.g., amphetamine, cocaine) dopamine agonists in rats often produces an increase in locomotor
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activity and the induction of various stereotyped oral
movements (sniffing, licking, and gnawing). The repeated
administration of these drugs results in the development
of behavioral sensitization, characterized by a progressive augmentation of these drug-induced motor behaviors. In humans, repeated exposure to drugs which directly or indirectly stimulate dopamine receptors often results in the delayed appearance of several severe, and
sometimes long-lasting, behavioral side-effects (e.g., amphetamine psychosis). It is widely assumed that the
neurobiological mechanisms mediating behavioral sensitization in animals are the same as those responsible for
the side-effects observed in humans (see Robinson and
Becker 1986; Kalivas and Weber 1988). Although it is
clear that the development of behavioral sensitization
requires the stimulation of dopamine receptors (Kuczenski and Leith 1981; Mattingly and Rowlett 1989;
Peris and Zahniser 1989), the specific drug-induced neurobiological changes mediating the development of behavioral sensitization are unknown.
Dopamine receptors exist in at least two distinct
subtypes possessing unique pharmacologic and biochemical properties (see Breese and Creese 1986; Clark and
White 1987, for review). Dopamine D 1 receptors stimulate adenylate cyclase activity, whereas dopamine 0 2
receptors are either unlinked to, or inhibit, this enzyme.
Dopamine agonists which induce behairioral sensitization (e.g., apomorphine, amphetamine, cocaine) result in
an increased stimulation of both D 1 and 0 2 dopamine
receptor subtypes. At present, there is still considerable
disagreement regarding the involvement bf specific dopamine receptor subtypes in the developme'nt of behavioral
sensitization. For example, Stewart an~ Vezina (1989;
Vezina and Stewart 1989) have conclu~ed that the development of sensitization to amphetamine is the result
of increased D 1 receptor stimulation, whereas Levy et al.
(1988) suggest that amphetamine-induced sensitization is
the result of 0 2 receptor stimulation. In contrast, there
is some evidence which suggests that the toncurrent stimulation of both 0 1 and 0 2 receptors niay be necessary
for the development of sensitization to cocaine (Peris and .
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Zahniser 1989) and methamphetamine (Ujike et al.
1989). Thus, although the overt behavioral effects of
these indirect dopamine agonists are similar, the
neurochemical mechanisms mediating the development
of behavioral sensitization to these agents may differ.
The objective of the present study was to determine
the involvement of specific dopamine receptor subtypes
in the development of behavioral sensitization to the
direct dopamine receptor agonist, apomorphine. Consequently, in three experiments rats were treated daily with
apomorphine in combination with either a selective D 1
or D 2 antagonist and then tested for sensitization following a challenge dose of apomorphine.

administered IP in a volume of 1.0 ml/kg. Control injections were
given using the appropriate vehicle using the same route and volume
as the corresponding drug injection.
Design and procedure. At the beginning of the experiment, the rats
were randomly assigned, in equal numbers, to one of six groups
comprising a two (agonist dose) x three (antagonist dose) factorial
design. On each of the first 21 days of the experiment each rat was
first injected with either 0 (vehicle), 30, or 100 mg/kg sulpiride and
then about 30 min later injected with either 0 (vehicle) or 1.0 mg/kg
apomorphine. The rats were returned to their home cage after the
daily injections without behavioral testing. Fol1owing this training
phase the rats were left undisturbed in their home cages for 6 days
prior to sensitization testing. On each of the 4 sensitization test
days, all rats received an injection ofapomorphine (5.0 mg/kg) prior
to activity testing. Activity testing began 15 min following the injection and was conducted for 20 min.

Experiment 1
Repeated apomorphine treatments in doses equal to or
greater than LO mg/kg produce a progressively greater
increase in locomotor activity when administered intermittently (Castro et al. 1985; Mattingly et al. 1988a,
1988b). This progressive increase occurs regardless of
whether the apomorphine injection is paired with the
activity testing environment, but is generally larger if
such pairing occurs (Mattingly and Gotsick 1989). Moreover, the development of sensitization to apomorphine
is completely blocked by the concurrent administration
of the mixed D,/D 2 dopamine receptor antagonist, haloperidol (Mattingly and Rowlett 1989). The purpose of
experiment l, therefore, was to determine. whether the
development of sensitization to apomorphine would also
be prevented by concurrent administration of the selective D 2 dopamine receptor antagonist, sulpiride.

Results and discussion

The results of the sensitization test phase are shown in
Fig. I. These data were analysed with a three-factor
mixed analysis of variance (ANOVA) using antagonist
dose and agonist dose as between factors and activity
session as a within factor. As may be seen in Fig. 1, the
three groups of rats pretreated with apomorphine (VEHAPO, 30 SUL-APO, 100 SUL-APO) for 21 days displayed a much greater increase in activity in response to
apomorphine than did rats receiving apomorphine for
the first time (VEH-VEH, 30 SUL-VER, 100 SULVEH), agonisteffect, F(l, 66) = 17.12, P<0.0001. More
important, this sensitization effect was not blocked by
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Materials and methods
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Subjects. Seventy-two male Wistar albino rats (Harlan Industries,
Indianapolis, IN) weighing between 250 and 300 g served as subjects. All rats were housed individually in a colony room with a 12-h

g1s

light-dark cycle and maintained with food and water available
continuously. All behavioral testing was conducted during the light
phase of the cycle.

I!!

Apparatus. Activity measures were taken in two BRS/Lehigh Valley
cylindrical activity drums (Model 145--03) that were 60 cm in diameter and 43 cm high. The interior of each drum was painted Hat
black, and the floor was made of 4 cm diamond-shaped wire mesh.
Each drum was located in a separate sound-attenuated experimental cubicle that was kept totally dark throughout testing.
Two banks of three infrared photocells were mounted on the
outside of each drum. The photocells \Vere approximately 12 cm
apart and 2.5 cm above the drum floor. The photocell banks were
connected to back-path eliminator diodes. Movement of the rat
through a photocell beam sent a single pulse to the counters. Simultaneous pulses (i.e., pulses spaced less than 0.05 s apart) such as
might occur when two beams are broken near their intersection
were recorded as a single count by this method. Thus, activity was
operationalized as the cumulative number of photobeam interruptions per unit time.
Drugs. Apomorphine hydrochloride (Sigma) was dissolved daily in
0.001 N HCL. It was injected SC in a volume of0.5 ml/kg. Sulpiride
(Sigma) was mixed daily in a I% glacial acetic acid solution and
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SESSIONS OF 20 MIN

Fig. 1. 'Mean activity counts across four 20 min sensitization test
sessions for rats chronically pretreated with sulpiride (0 (VEH), 30,
or 100 mg/kg SUL) and apomorphine (0 (YEH) or 1.0 mg/kg,
APO). All rats received 5.0 mg/kg apomorphine 15 min before
each test session. •-• 100 SUL-APO; 0- - -O 100 SUL-YEH;
"-" 30 SUL-APO; 6- - -6 30 SUL-YEH; •-• YEH-APO;
0---0 YEH-YEH
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concurrent sulpiride treatments. That is. the apomorphine-induced activity response of rats pretreated with
sulpiride and apomorphine did not differ from that of
rats pretreated with only apomorphine (i.e., VEH-APO
group). Likewise, it is clear from Fig. 1 that repeated
treatmen.ts of sulpiride without apomorphine did not
significantly affect subsequent sensitivity to apomorphine in this test. The ANOVA performed on these data
indicated that neither the main effect of antagonist dose
nor the Antagonist dose x Agonist dose interaction was
significant. The main effect of test session, however, was
significant [F(3, 198) = 120.68, P<0.0001], as all groups
displayed a progressively greater increase in activity in
response to apomorphine across the four test sessions.

Experiment 2
In experiment 1, rats pretreated with apomorphine displayed significant sensitization and this sensitization was
not blocked by the D 2 antagonist sulpiride. From the
results of experiment I, however, we have absolutely no
evidence that sulpiride was effective in blocking dopamine receptors. The purpose of experiment 2, therefore,
was to systematically replicate experiment I and to determine the acute effect of sulpiride on apomorphineinduced locomotor activity. Consequently, four groups
of rats were injected daily with sulpiride and/or apomorphine and tested for locomotor activity for 7 days. Following this brief subchronic training phase, all rats were
tested for activity following an apomorphine injection
for four additional days. Experiment 2 differed from
experiment I in the following ways: I) only the
I 00 mg/kg dose of sulpiride was used; 2) the rats were
tested for activity during the training phase; 3) the training phase was only conducted for 7 days; and 4) a
1.0 mg/kg dose of apomorphine was used in both the
training phase and the sensitization test phase.
Materials and methods
Subjects, apparatus, and drugs. The subjects were 35 male Wistar

albino rats (Harlan Industries, Indianapolis, IN) experimentally
naive and weighing between 250 and 350 g at the beginning of the
experiment. They were housed and maintained as in experiment I.
The photocell activity drums used were also the same as in experiment 1. Like,vise, the drugs were obtained, prepared, and administered as in experiment 1.

Design and procedure. The rats \Vere randomly assigned to one of
four groups {n=8-9 each) comprising the 2 (antagonist dose: 0 or
IOO mg/kg sulpiride) x 2 (agonist dose: 0 or 1.0 mg/kg apomorphine) factorial design. On day 1 of the training phase each rat was
first injected IP with either sulpiride or vehicle and returned to its
homecage. Thirty minutes later apomorphine or vehicle was injected SC and the animal was again returned to its homecage. Fifteen
minutes follo\ving the second injection each rat was placed in the
activity drum and activity was measured for 20 min. This injectiontest procedure was repeated daily for 7 days. Sensitization testing
began 24 h after the last training day and was conducted for 4 days.
On each of these days all rats were tested for locomotor activity
15 min after a challenge dose of 1.0 mg/kg apomorphine.
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Fig. 2. Mean activity counts across the training (l-7) and sensitization test (8-11) sessions for rats pretreated with 100 mg/kg sulpiride
(JOO SUL) or vehicle (VEH) and 1.0 mg/kg apomorphine (APO) or
VEH. All rats received a single injection of 1.0 mg/kg APO prior
to each sensitization test session. For symbols see legend of Fig. l

Results and discussion
Training sessions 1-7. The mean activity counts for the
groups during the training phase (sessions 1-7) are
shown in the left panel of Fig. 2. As shO\yn in this figure,
rats injected with apomorphine only (YEH-APO) displayed a progressively greater increase in locomotor activity across the 7 test days and were more active than
control rats (VEH-VEH) across sessions 4-7. In contrast,
rats treated with sulpiride only (! 00 SULcVEH) were less
active than control rats across the seven sessions. More
important, as may seen in Fig. 2, sulpiride given concurrently with apomorphine completely blocked the activity
increasing effect of repeated apomorphine treatments.
Indeed, the activity of rats given sulpiriOe and apomorphine (100 SUL-APO) appeared compi\rable to that of
the vehicle control rats (VEH-VEH) across sessions 3-7.
As expected from inspection of Fig. 2, the mixed factor
ANOVA performed on these data rev~aled significant
main effects of agonist dose, antagonist dose, and a
significant Agonist x Antagonist x Day
interaction
[F(l, 31)=9.89, P<O.Ol, F(l, 31)=36.22, P<0.0001,
and F(6, 186)=4.72, P<0.001, respectively].
'
Sensitization test sessions 8-11. As may he seen in Fig. 2,
rats pretreated with sulpiride for 7 days increased activity
on session 8 when given only an apombrphine injection.
This increase, however, was greater forjsulpiride-treated
rats which had also received apomorphil)e pretreatments.
Indeed, the rats given concurrent sulpiride-apomorphine
(100 SUL-APO) pretreatments were as ltctive on session
8 as rats given only apomorphine (VEH1APO) during the
training phase. In contrast, rats pretreated with only
sulpiride (100 SUL-VEH) increased activity to a level
comparable to that of the vehicle control rats (VEHVEH) on session 8. The hyperactivit~ of the apomorphine pretreated rats was maintained across sessions

'
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9-11 even though the rats pretreated with vehicle
(100 SUL-YEH, YEH-YEH) progressively increased activity across these sessions as they too became more
sensitive to apomorphine. These findings suggest that
concurrent sulpiride treatments did not block the development of behavioral sensitization to apomorphine.
Consistent with this interpretation, the mixed factor
ANOYA performed on the activity counts across sessions 8-11 revealed only a significant main effect of
agonist and a significant main effect of session
[F(l, 31)= 9.51, P< 0.01, and F(3, 93) = 14.71, P< 0.0001,
respectively]. Neither the main effect of antagonist nor
any of the interactions containing antagonist as a factor
were significant.
Experiment 3

It is evident from the results of experiment 2 that the D 2

antagonist sulpiride blocks the progressive increase in
locomotor activity induced by repeated treatments with
the mixed dopamine receptor agonist apomorphine.
However, consistent with experiment I, the results of
experiment 2 clearly indicate that sulpiride does not
prevent the development of behavioral sensitization to
apomorphine. In contrast, concurrent treatment with
the mixed D 1/D 2 dopamine antagonist haloperidol completely blocks the development of sensitization to apomorphine (Mattingly and Rowlett 1989). Taken together, these results suggest that the development of behavioral sensitization to apomorphine is either exclusively
related to the stimulation of D 1 dopamine receptors, or
that repeated stimula\ion of either D 1 or D 2 receptors
might be sufficient to induce sensitization. The purpose
of experiment 3, therefore, was to determine whether the
development of behavioral sensitization to apomorphine
could be prevented by a selective blockade of dopamine
D 1 receptors. Consequently, four groups of rats were
injected daily with apomorphine and/or the selective D 1
dopamine receptor antagonist SCH 23390 and tested for
changes in locomotor activity. The design and procedure
was the same as in experiment 2, except SCH 23390
rather than sulpiride was used.

Materials and methods
Subjects, design and procedure. Forty male Wistar albino rats (Harlan Industries, Indianapolis, IN) weighing between 250 and 350 g
served as subjects. The rats were randomly assigned, in equal numbers, to one of four training groups comprising the 2 (antagonist
dose: 0 or 0.5 mg/kg SCH 23390, Research Biochemicals) x 2 (agonist dose: 0 or 1.0 mg/kg apomorphine) factorial design. The
apparatus and procedure was the same as in experiment 2. SCH
23390 was dissolved daily in distilled H 2 0 and injected IP in a
volume of 1.0 mlfkg. Apomorphine was obtained, prepared, and
administered as described previously.

Results and discussion
Training sessions 1-7. The mean activity counts of the
four groups across the seven training sessions are pre-
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Fig. 3. Mean activity counts across the training (I-7) and sensitization test (8-11) sessions for rats pretreated with 0.5 mg/kg SCH
23390 (SCH) or vehicle (VEH) and 1.0 mg/kg apomorphine (APO)
or YEH. All rats received a single injection of 1.0 mg/kg APO prior
to each sensitization test session. •-• SCH-APO; D- -D SCHVEH; •-• VEH-APO; 0---0 VEH-VEH

sented in Fig. 3. As shown in this figure, repeated apomorphine treatments alone (YEH-APO group) resulted
in a progressively greater increase in activity with each
injection. This progressive increase in apomorphineinduced activity, however, was completely blocked by
concurrent SCH 23390 treatments (see SCH-APO
group). Indeed, SCH 23390 treatments greatly depressed
activity compared to the vehicle control group (VEHYEH), regardless of whether apomorphine was also
given (see SCH-YEH, SCH-APO groups). As expected,
the three-factor mixed ANOYA performed on these data
revealed significant main effects of agonist dose, antagonist dose and a significant Agonist x Antagonist interaction [F(l, 36) = 5.27, P< 0.05, F(l, 36) = 110.56,
P<0.0001, and F(l, 36)=9.21, P<0.01, respectively].
The session effect was also significant [F(6, 216)=4.01,
P< 0.001], as was the Agonist x Session [F(6, 216)= 19.58,
P< 0.0001], and the Agonist x Antagonist x Session
interaction [F(6, 216)=9.06, P<0.0001. These significant interactions reflect the fact that only the YEH-APO
groups displayed a significant increase in activity across
the seven sessions, and the activity level of the YEH-APO
group did not increase above that of the YEH-YEH
control group until the third activity test session.
Sensitization test sessions 8-11. As may be seen in Fig. 3,
the SCH 23390-pretreated rats (SCH-YEH, SCH-APO)
increased activity on session 8, when given only an injection of apomorphine, to a level comparable to that of rats
previously treated only with vehicle (YEH-YEH). Moreover, this increase was the same for both SCH 23390
pretreatment groups. That is, rats pretreated with apomorphine and SCH 23390 (SCH-APO) during the training phase were no more sensitive to apomorphine on
session 8 than rats pretreated with only SCH 23390
(SCH-YEH). In other words, concurrent SCH 23390
treatments along with apomorphine completely blocked
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the development of sensitization to apomorphine. The
mixed factor ANOVA performed on the mean activity
counts across these four sensitization test sessions
indicated a significant main effect of antagonist
[F(l, 36) = 5.73, P < 0.05] and a significant Antagonist x
Agonistinteraction [F(l, 36)=5.98, P<0.05]. This latter
interaction was further analysed using a Newman-Keuls
post hoc test to compare the mean activity counts of the
four groups collapsed across the four sensitization test
sessions. The results of this analysis indicated that overall, the rats pretreated with only apomorphine (VEHAPO) during the training phase were significantly more
active than the other three pretreatment groups [P< 0.05
in each case]. In contrast, this analysis indicated that
overall, the rats pretreated with SCH 23390 and apomorphine (SCH-APO) were significantly less active than the
other three groups [P< 0.05 in each case]. The apomorphine-induced activity level of rats pretreated with only
SCH 23390 (SCH-YEH) did not differ across these sessions from that of the rats pretreated with only vehicle
(VEH-VEH).
The ANOV A performed on these data also revealed
a significant session effect [F{3, 108)= 19.23, P<0.0001],
as overall, the rats tended to increase activity across
sessions. This increase, however, was greater for rats
receiving apomorphine for the first time than for rats
which were pretreated with apomorphine [Agonist x
Session interaction, F(3, 108) = 8.58, P < 0.01].
In summary, the results of experiment 3 indicate that
SCH 23390 significantly depressed locomotor activity in
control rats and acutely blocked the activity-increasing
effect of repeated apomorphine treatments. More important, concurrent SCH 23390 treatments completely
prevented the development of behavioral sensitization to
apomorphine.

Discussion
It is evident from the present results that repeated treatment of rats with the direct dopamine receptor agonist,
apomorphine, results in the development of behavioral
sensitization. This finding is consistent with previous
work (e.g., Castro et al. 1985; Mattingly et. al 1988b).
Further, the results of the present experiments clearly
indicate that the activating effects of apomorphine on
locomotor activity may be blocked by concurrent treatment with either a selective D 1 or D 2 antagonist. In
experiment 2, the D 2 antagonist, sulpiride, blocked the
effects of apomorphine on locomotor activity, and in
experiment 3, the activity-increasing effects of apomorphine were prevented by the selective D 1 antagonist SCH
23390. Taken together, these findings suggest that the
concurrent stimulation of both D 1 and D 2 dopamine
receptors is neccessary for the expression of apomorphine-induced locomotor activity. Consistent with these
results, recent evidence suggests that the expression of
other dopamine agonist-induced behavioral and electrophysiological effects also requires the concomitant
stimulation of both D 1 and D 2 dopamine receptors
(Amalric et al. 1986; Carlson et al. 1987; Plaznik et al.

1989; Ross et al. 1989; Bergman et al. 1990; Moore and
Axton 1990).
In contrast to the involvement of both D 1 and D 2
receptors in the expression of apomorphine-induced
locomotor activity, the development of behavioral sensitization to apomorphine appears to require the repeated stimulation of only the D 1 receptor. Indeed, in
both experiments 1 and 2, the concurrent administration
of the selective D 2 antagonist, sulpiride, in doses which
blocked apomorphine-induced increases in activity, did
not prevent the development of behavioral sensitization.
That is, rats pretreated daily with sulpiride and apomorphine combined displayed an enhanced locomotor activity response to a challenge dose ofapomorphine comparable to that observed in rats pretreated with only apomorphine. However, in experiment 3·, the concurrent
administration of the D 1 selective dopamine receptor
antagonist, SCH 23390, blocked both the: expression and
the development of behavioral sensitization to apomorphine. Rats given both SCH 23390 and apomorphine in
this experiment responded to a subsequent challenge
dose of apomorphine in a manner similar to rats pretreated with only vehicle. These data suggest, of course,
that the development of behavioral sensitization to apomorphine is mediated by dopamine D 1 receptor stimulation.
In agreement with these findings, Vezina and Stewart
(1989; Stewart and Vezina 1989) have recently reported
that although both D 1 and D 2 selective antagonists
blocked the acute locomotor activating effects of amphetamine, only the D 1 receptor antagonist SCH 23390
blocked the development of behavioral sensitization to
amphetamine. Thus, like apomorphine, the development
of behavioral sensitization to amphetamine appears to be
related to D 1 receptor stimulation. Based upon both
behavioral and electrophysiological data, other researchers have also concluded that repeated dopamine D 1 receptor stimulation may be the crucial factor neccessary
for the induction of agonist-induced behavioral sensitization (e.g., Braun and Chase 1988; Criswell et al. 1989;
Henry and White 1989). But, as noted previously, not all
investigators share this view (e.g., Levy et al. 1988). Peris
and Zahniser (1989), for example, found that the augmentation in amphetamine-induced 3 H-dopamine release from
striatal slices observed after a single pretreatment with
cocaine could be blocked by either the D 1 selective antagonist, SCH 23390, or the D 2 selective antagonist,
sulpiride. Similarly, Ujike et al. (1989) reported that the
augmentation of locomotor activity and stereotypic behavior observed in rats following repeated methamphetamine administration was blocked by concurrent
treatments with either SCH 23390 or tJie D 2 antagonist,
YM 09151-2. These results, of course, implicate both D 1
and D 2 receptors in the development of behavioral sensitization. At present, the basis for these discrepancies is
unknown. Since ·apomorphine, amphetamine, and cocaine enhance dopaminergic activity through different
mechanisms, it is possible that the neurochemical mechanisms underlying the development of behavioral sensitization to each of these drugs may differ (cf Rowlett
et al. 1991). However, it is not clear why different mech-
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anisms would mediate the development of behavioral
sensitization to amphetamine and methamphetamine (cf
Stewart and Vezina 1989; Ujike et al. 1989), since these
drugs have similar mechanisms of action. This latter
discrepancy is probably related to the differences in behavioral measures and/or the use of different selective
antagonists among the studies.
Several hypotheses have been proposed to account for
the development of behavioral sensitization to dopamine
agonists, including conditioning, autoreceptor tolerance,
and an augmented agonist-induced release of dopamine
(see Robinson and Becker 1986). The present results are
inconsistent with each of these views. A conditioning
explanation of behavioral sensitization, for example, suggests that the progressive increase in apomorphineinduced locomotor activity is related to the development
of a conditioned locomotor activity response to the environmental stimuli associated with drug exposure. But
in the present study, behavioral sensitization still developed to apomorphine in experiment 2 even though the
activating effects of repeated apomorphine treatments
were completely blocked by sulpiride during the training
phase. Although this finding alone does not completely
rule out the involvement of conditioning mechanisms, it
is consistent with other work which suggests that behavioral sensitization to apomorphine develops through
both associative and nonassociative processes (cf Gold et
al. 1988; Mattingly et al. 1988; Mattingly and Gotsick
1989).
The autoreceptor tolerance explanation of behavioral
sensitization suggests that dopamine autoreceptors
which appear to be inhibitory with respect to locomotor
activity, become subsensitive with repeated exposure to
non-selective agonists such as apomorphine and amphetamine. Thus, with repeated agonist treatments the
inhibitory effects of autoreceptor stimulation on dopamine synthesis, release, and firing rate progressively decrease and consequently, agonist-induced locomotor activity increases (see Robinson and Becker 1986, for review). In the present study, doses of the D 2 antagonist
sulpiride large enough to block both pre- and postsynaptic D 2 receptors (cf Vezina and Stewart 1989), did
not prevent the development of behavioral sensitization.
Moreover, the dose of the D, receptor antagonist SCH
23390 which prevented the development of behavioral
sensitization in experiment 3, does not interact with
dopamine autoreceptor function (Lappalainen et al.
1990). Thus, although a significant amount of evidence
suggests that autoreceptors do become less sensitive with
repeated agonist treatments, autoreceptor tolerance
alone cannot account for the development of behavioral
sensitization (see Ackerman and White 1989; Braun and
Chase 1988; Mattingly et al. 1988; Vezina and Stewart
1989).
Finally, much recent evidence suggests that repeated
amphetamine treatments result in an augmented amphetamine-induced release of dopamine (Kuzcenski and
Segal 1988, 1989; Robinson et al. 1988) which coincides
with the development of behavioral sensitization to amphetamine. Similarly, the development of behavioral sensitization to cocaine appears to be related to an increase

in extracellular dopamine levels in the nucleus accumbens (Kalivas and Duffy 1990). But while these presynaptic effects may account for the development of behavioral
sensitization to indirect dopamine agonists such as amphetamine and cocaine, which exert their effects primarily by inducing the release and/or blocking the re-uptake
of dopamine, these presynaptic effects cannot explain the
development of sensitization to direct dopamine receptor
agonists such as apomorphine (cf Braun and Chase 1988;
Zahniser et al. 1988; Vaughn et al. 1990). At present, the
only presynaptic effect reported which may be related to
the development of sensitization to apomorphine is an
increase in steady-state dopamine synthesis (Vaughn et
al. 1990; Rowlett et al. 1991).
In conclusion, the present results clearly indicate that
the expression of dopamine agonist-induced behavioral
effects requires some minimal level of stimulation of both
D 1 and D 2 dopamine receptors. In contrast, the development of behavioral sensitization to apomorphine appears
to require the repeated stimulation of only the D 1 receptor. This finding with apomorphine is consistent with
recent work with amphetamine. Finally, the results of the
present experiments are inconsistent with conditioning
and autoreceptor tolerance explanations of apomorphine-induced behavioral sensitization.
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Abstract. The non-selective excitatory amino acid antagonist kynurenic acid, which does not readily cross the
blood-brain barrier, dose-dependently attenuated the behavioral signs of naltrexone-precipitated withdrawal in
morphine-dependent rats following both intra ventricular
and subcutaneous administration. However, intraventricular and subcutaneous administration of kynurenic
acid had different effects on individual withdrawal behaviors. Moreover, single unit recordings in anesthetized
animals showed that intraventricular, but not subcutaneous, kynurenic acid administration attenuated the
withdrawal-induced increased firing of locus coeruleus
neurons. These studies indicate that: (1) both central and
peripheral excitatory amino acid receptors may play an
important role in opiate withdrawal; and (2) excitatory
amino acid antagonist treatments might be developed to
reduce opiate abstinence symptoms in man.
Key words: Kynurenic acid - Locus coeruleus- Excitatory amino acid - Morphine - Opiate withdrawal

The mechanism of opiate withdrawal is not completely
understood. In man, opiate withdrawal is characterized
by nausea, anxiety, insomnia, hot and cold flashes, mus-

cle aches, perspiration, diarrhea, and craving for the drug
(Kolb and Himmelsbach 1938). A variety of neurotransmitter systems have been hypothesized to play a role in
opiate withdrawal including the brain noradrenergic system (see Redmond and Krystal 1984). The role of the
brain noradrenergic system in opiate withdrawal is supported in part by the finding that the noradrenergic cells
of the locus coeruleus (LC) greatly increase their activity
during antagonist-precipitated withdrawal (Aghajanian
1978; Valentino and Wehby 1989) and that this increased
activity correlates temporally with withdrawal behavior
(Rasmussen et al. 1990). In addition, clonidine, an alpha-2 agonist, decreases the activity of LC neurons
Ojj'print requests to: K. Rasmussen

during morphine withdrawal (Aghajanian 1978), suppresses withdrawal behaviors after direct infusion into
the LC (Taylor et al. 1988), and is used to minimize
opiate-withdrawal symptoms in man (Gold et al. 1978).
However, ST-91, an alpha-2 agonist that does not readily cross the blood-brain barrier, can also suppress morphine-withdrawal behaviors after either peripheral or
central administration, indicating that both central and
peripheral noradrenergic systems play a role in the expression of many opiate-withdrawal behaviors (Taylor
et al. 1988).
Kynurenic acid, a naturally occurring metabolite of
tryptophan that is found in brain tissue (Stone et al.
1987), is a non-selective excitatory amino acid antagonist
(Perkins and Stone 1982) that does not readily cross the
blood-brain barrier (Swartz et al. 1990). Recent studies
have shown that intraventricular administration of kynurenic acid greatly attenuates the withdrawal-induced
activation of LC neurons (Rasmussen and Aghajanian
1989; Tung et al. 1990). Therefore, the present study was
conducted to evaluate the effects of intraventricular administration of kynurenic acid on morphine-withdrawal
behaviors, and further, to evaluate the effects of systemic
administration of kynurenic acid on both the behavioral
signs of morphine withdrawal and the withdrawalinduced increase in firing of LC neurons.
Materials and methods
Opiate dependence was induced in male Sprague-Dawley rats
(Charles River, 250-350 g) by the subcutaneous pellet implantation
method (Jlay el al. 1969; Blassig et al. 1973). Under halathane
anesthesia, animals were implanted with either morphine pellets
(NIDA: 75 mg morphine base) or sham pellets. One pellet was
implanted daily for 2 days. Withdrawal was induced 48 h after the
last pellet implantation; the pellets were removed under halothane
anesthesia 2-3 h before precipitating withdra\val. Withdrawal was
induced by administering the opiate antagonist naltrexone HCI
(IO mg/kg; Sigma) subcutaneously (SC).
The severity and time course of opiate withdrawal was assessed
as described previously (Rasmussen et al. 1990). Briefly, animals
were studied in pairs in.clear plexiglass cages (11 in x 7 in x 5 in) and
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